Celldex Therapeutics, Inc. (CLDX) stock is up 714.48% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives CLDX stock a score of 82 out of a possible 100.
That rank is influenced by a short-term technical score of 97. CLDX's rank also includes a long-term technical score of 81. The fundamental score for CLDX is 69. In addition to the average rating from Wall Street analysts, CLDX stock has a mean target price of 26.333. This means analysts expect the stock to gain 46.29% over the next 12 months.
What's Happening with CLDX Stock Today
Celldex Therapeutics, Inc. (CLDX) stock is lower by -1.32% while the S&P 500 is up 0.55% as of 10:37 AM on Tuesday, Dec 15. CLDX is lower by -$0.24 from the previous closing price of $18.24 on volume of 133,171 shares. Over the past year the S&P 500 has gained 14.92% while CLDX is up 714.48%. CLDX lost -$2.22 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Celldex Therapeutics, Inc. (CLDX) Stock.
